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In Morocco, the resistance monitoring of Anopheles labranchiae larvae to temephos is done using discriminating concentration of
0.125mg, which is half of the WHO recommended dose for Anopheles. However, this dosage seemed to be too high to allow an
early detection of the resistance and its revision was found necessary. The present study was carried out during May-June 2008
and 2009 in nine provinces from the north-west of the country. The aim was to determine the lethal concentrations LC100 of
temephos for the most susceptible populations and to deﬁne the discriminating dosage as the double of this value. The bioassays
were conducted according to WHO standard operating protocol to establish the dose-mortality relationship and deduct the LC50
and LC95. The results of this study indicated that the LC100 obtained on the most susceptible populations was close to 0.05mg/L.
Therefore, the temephos discriminating dosage for susceptibility monitoring of An. labranchiae l a r v a ei nM o r o c c ow a ss e tt ob e
0.1mg/L.
1.Introduction
In Morocco, last autochthonous malaria case was registered
in 2004. Since then a vector control program was established
to prevent a possible return of malaria transmission. It
is mainly based on the larval control of the main vector:
Anopheles labranchiae (Falleroni 1926) [1]. This control
includes integrated management using environmental meth-
ods and larvivorous ﬁsh (Gambusia holbrooki) as biological
control. Insecticides are used as the last option but they
take an important place in the National Malaria Control
Programme (NMCP).
Larval treatments started in the 1950’s using DDT [2]. In
1978, an organophosphate insecticide, the temephos (Abate
500 EC) was introduced, and since then, it has been the only
insecticide used for An. labranchiae larval control.
The monitoring of An. labranchiae susceptibility to
insecticides used in larval and adult control is an essential
component of the NMCP. This activity has started with the
launch of the programme following WHO protocol, using
discriminating dosage [3]. The ﬁrst susceptibility tests of
Anopheles labranchiae to temephos were carried out before
its introduction for larval control using concentrations
supplied by WHO (0.005, 0.025, 0.125, 0.625mg/L). Results
of these tests, carried out on natural populations, showed
that the lowest dosage involving regularly 100% mortality
was 0.125mg/L. This concentration was considered as a
speciﬁc discriminating dose for Moroccan An. labranchiae
and was used in routine resistance monitoring. Although
this dose represents half of the diagnostic concentration
recommended by WHO (0.25mg/L) [4]f o rAnopheles, this
is higher than the operational dosage of temephos that is still
eﬀective for larval control. Indeed, operational treatments
are made using a dosage of 50g/ha, corresponding to a
concentration of 0.05to 0.1mg/L for breeding sites, respec-
tively, of about 10 and 5cm of depth. The diagnostic dose of2 Malaria Research and Treatment
0.125mg/L seems to be too high to allow an early detection
of the resistance, and so its revision was found necessary.
The present study was carried out to determine a more
accurate diagnostic dose, for the larvae of An. labranchiae
from Morocco, if possible lower than the operational dose
to early detect a signiﬁcant reduction of insecticide suscepti-
bility among ﬁeld populations. This study will also serve as
reference data which could be applied in countries around
Mediterranean sea, particularly Algeria, Tunisia, Italy, and
France where An. labranchiae is present and could constitute
a risk for malaria transmission [5–8].
2.MaterialandMethods
2.1. Study Areas. An. labranchiae is an eurygamic species.
It is almost impossible to rear in insectarium and hence
diﬃcult to have a susceptible reference strain to estimate its
baseline susceptibility. So, we attempted to search for a wild
population as susceptible as possible, in regions where the
selection pressure by insecticide treatment was low. Pressure
of organophosphate (OP) used in public health is low as
temephos is the ﬁrst and the only OP used in Anopheles
larvae control, and DDT was the only insecticide used in
adult control. However, pressure of insecticides used in
agriculture could be important because An. labranchiae is
abundant in the agricultural zones particularly in the north
western of the country [9] where the main culture practices
are wheat, corn, sugar cane, and rice cultivation. To mitigate
this way, larvae were collected in sites as far as possible from
cultivation areas. Hence, the study was carried out in nine
provinces (Figure 1).
2.2.Mosquitoes. BecauseMoroccoisinaphaseofprevention
of malaria reintroduction, the vector An. labranchiae is
submitted to regular controls. Consequently, its density is
lowanditwasnoteasytoﬁndmanypositivebreedingsitesin
suﬃcient density to realize bioassays. We were then forced to
realize tests in sites where density was allowable, generally far
from villages. Larvae were collected, using standard dipping
method, in diﬀerent biotopes (swamps, rivers, rice ﬁelds)
during May-June 2008 and 2009 (Table 1). Specimens were
identiﬁed morphologically [10].
2.3. Bioassays. Bioassays were carried out following WHO
standard procedures to establish the dose-mortality relation-
ship and to calculate lethal concentrations LC50 and LC95
(concentrations involving, resp., the death of 50% and 95%
of the tested population) [11]. Tests were carried out on the
thirdandfourthinstarlarvae.Rangesof5to6concentrations
of temephos and control were prepared to determine the
LC50 and LC95 for each population. For each dilution, 3 to 4
replicates were done, with 15 to 25 larvae each. Larvae were
placed in 99mL of water; 1mL of adequate concentration of
temephos was then added. After 24 hours of exposition at
ambient temperature (21-22◦C) without feeding, alive and
dead larvae were counted. When it was possible, 2 tests were
conducted on the same population in the same experimental
conditions in 2 diﬀerent days. Tests involving less than four
sets with mortalities diﬀerent from 0 and 100% or with
mortality in control higher than 20% were not considered
[12].
Results analysis was made using log-probit analysis soft-
ware (WinDL version 2.0) developed by CIRAD-CA/MABIS
[13]. It allows calculating LC50, LC95, and their conﬁdence
intervals.
Diagnostic concentration was calculated as the double of
the observed LC100 of the most susceptible populations.
3. Results
A total of more than 7,000 larvae were tested for 18 diﬀerent
tests conducted in 12 villages. Among these bioassays, only
12 were valid. Among the six tests considered as invalid,
mortality in control was superior to 20% in 2 tests, and there
were 4 tests involving less than four sets with mortalities
diﬀerent from 0 and 100%.
Results of bioassays are presented in Table 2.
The LC95 varies from 0.036 to 0.105mg/L among
the diﬀerent populations, representing a ratio less than
3 folds. The most susceptible populations were collected,
respectively,inBenslimaneandMeknes.Theleastsusceptible
populations were collected in Khemisset and Larache.
Thelowestconcentrationinvolving100%ofmortalityon
the natural populations is of 0.0625mg/L. It was obtained
on Ben Slimane and Boucharen populations. As the highest
tested concentration producing a mortality less than 100%
is 0.025mg/L, the real LC100 should be situated between
0.025mg/L and 0.0625mg/L.
Concentration of 0.125mg/L did not involve 100%
mortality in the population of Sbih (Sidi Kacem) suggesting
the emergence of a beginning of resistance.
4. Discussion
The standardized bioassays on larvae or adults using a
discriminatingdosageofinsecticidesarelargelyemployedfor
the resistance monitoring of mosquito populations targeted
by vector control programmes [14]. This method has the
advantage of being simply used, fast, and inexpensive, as
well as of giving reproducible results and requiring only a
small number of specimens compared to the conventional
bioassays.
The discriminating dosage corresponds to the theoretical
LC100 of susceptible individuals obtained by extrapolating
the regression curve (probit mortality/log dosage) to a
mortality rate of 99.9% [15] .I np r a c t i c ea n dt ok e e pas a f e t y
margin, this dosage corresponds to twice the LC99.9% or
preferentiallytwice the lowest dosage giving 100% of mortal-
ity of a fully susceptible population, since the LC99.9% has a
lowstatisticalvaluewhentheslopeofprobitlineisloworthe
population is heterogeneous.
The temephos discriminating dosage, established by
WHO, for the genus Anopheles is 0.25mg/L. Afterward, it
was stated locally for a limited number of species [16].
For An. Hyrcanus, this dose was set at 0.025mg/L and it
was 0.625mg/L for An. sacharov that belongs to the sameMalaria Research and Treatment 3
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Figure 1: Map of Morocco showing provinces where An. labranchiae populations were sampled.
Table 1: Details of larval breeding sites which were sampled.
Population Province Geographical coordinates Breeding site Type of breeding site
Longitude Latitude
Sidi Allal Msader Khemisset 06◦02  W3 3 ◦44  NR i v e r P e r m a n e n t
Beggara Larache 06◦06  W3 5 ◦10  N Swamps Permanent
Boucharen Larache 06◦04  W3 5 ◦07 NR i c e ﬁ e l d T e m p o r a r y
Ain Aghbal Meknes 05◦27  W3 3 ◦40  NR i v e r P e r m a n e n t
Ben Slimane Ben Slimane 07◦04  W3 3 ◦38  ND a y a T e m p o r a r y
Skhirat Skhirat-Temara 07◦05 W3 3 ◦50  N Swamps Permanent
Ain Elouali Fes 004◦54  W3 4 ◦07  NR i v e r P e r m a n e n t
Rabat Rabat 06◦46  W3 3 ◦58  N Swamp Temporary
Sbih Sidi Kacem 05◦26  W3 4 ◦24  N Swamps Permanent
Sehoul Sale 06◦35  W3 3 ◦51  NS w a m p s T e m p o r a r y
complex as An. labranchiae. In Morocco, before the ﬁrst
use of temephos, 0.025mg/L did not involve systematically
100% mortality on populations having never been in contact
with this product, and so they were expected to be fully
susceptible. The discriminating dosage would have been
around or higher than 0.05mg/L. As a compromise the
concentration of 0.125mg/L was chosen and was probably
superior to the real discriminating dosage.
Bioassays carried out by resistance monitoring sentinel
sites of Khemisset, Meknes, and Tetouan between 2004
and 2008 showed that several populations used to have a
LC100 sometimes equal to 0.025mg/L or slightly higher.
Accordingly, the LC100 of the most susceptible populations
in Morocco was found to be 0.05mg/L. This dose allows
for determining the diagnostic dosage of temephos for
An. labranchiae to be 0.1mg/L, which is ﬁnally very close4 Malaria Research and Treatment
Table 2: Susceptibility of An. labranchiae larvae to temephos inmg/L.
Province Population LC50 (CI) LC95 (CI) LC100
Khemisset Sidi Allal Msader 0.0198 (0.0052–0.0947) 0.1058 (0.0407–0.4210) >0.05
0.0196 (0.0016–0.0295) 0.0676 (0.0413–0.3013) >0.05
Sale Shoul 0.0098 (0.0074–0.0121) 0.0853 (0.0571–0.1632) >0.05
0.0094 (0.0078–0.0112) 0.0693 (0.0500–0.1090) >0.05
Larache Boucharen 0.0079 (0.0061–0.0101) 0.0586 (0.0391–0.1088) 0.0625
Beggara 0.0186 (0.0127–0.0262) 0.1002 (0.0622–0.2301) 0.1250
Ben Slimane Ben Slimane 0.0084 (0.0072–0.0098) 0.0362 (0.0288–0.0491) 0.0625
0.0208 (0.0186–0.0233) 0.0537 (0.0447–0.0692) 0.1250
Skhirat-Temara Skhirat 0.0067 (0.0055–0.0080) 0.0485 (0.0366–0.0703) 0.1250
Rabat Rabat 0.0188 (0.0073–0.0343) 0.0688 (0.0368–0.9785) 0.1250
Sidi Kacem Sbih 0.0301 (0.0223–0.0399) 0.0967 (0.0663–0.1961) 0.2500
Meknes Ain Aghbal 0.0178 (0.0160–0.0197) 0.0371 (0.0314–0.0480) 0.1250
LC50/LC95: lethal concentrations for 50% and 95% of larvae with conﬁdence intervals (CI) at 5% level.
LC100: observed concentration involving 100% of mortality.
to the diagnostic concentration previously used by the
national control programme and which could be higher than
operational dose.
Results of this study show that, with the exception of Sidi
Kacem population where a low resistance was suspected, all
testedpopulationsarestillsusceptibletotemephos.Although
temephos is used in vector control in Morocco within
the framework of a resistance management programme
which privileges the environmental control and the use of
larvivorous ﬁshes as biological control, it is essential that the
NMCP have replacement insecticides before the emergence
of Anopheles labranchiae resistance to temephos and the
failure of the present vector control program. Attention
must be steered towards the use of microbial control
agents and insect growth inhibitors taking into account cost
eﬀectiveness, feasibility, and respect of the nontarget fauna
and the environment.
The adoption of this discriminating dosage will allow
simplifying the procedure for monitoring the susceptibility
of An. labranchiae to temephos in the diﬀerent provinces of
Morocco.
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